This sense of resignation vanished after she underwent the TaNK cell therapy, Ms. Scott explained. The treatment has renewed her hope for the future. "I think to myself, 'What if I live to my 70s or my 80s?'" she said. "I want to stay healthy and live to be an old person."

Researchers at the Royal Free, led by principal investigator Dr. Panos Kottaridis, are currently recruiting patients for the clinical trial of the TaNK cell therapy, which has been licensed to Coronado BioSciences, a U.S.-based biopharmaceutical company. Three patients enrolled to date, including Ms. Scott, had failed all prior therapies before admission to the study.

"The results so far are very encouraging, as three patients with refractory disease enjoy long-term remission," Dr. Kottaridis said. "However, this is a Phase I study that has been designed to assess toxicity as the main end point, efficacy being a secondary one. It is very important for us to be able to recruit more patients and complete the current phase before moving to a multicenter international study demonstrating favorable clinical outcome."

Readers who would like to learn more about the study and patients who are interested in enrollment should visit the Cancer Research UK trial database at http://www.cancerhelp.org.uk/trials/trials/trial.asp?=&trialno=15617, contact Dr. Kottaridis by e-mail (panagiotis.kottaridis@ro
'/>"/>